Screener
Arcus Biosciences RCUS EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | — | — | — | — |
| Net income (loss) | $(91) | — | $(219) | $(112) |
| Net income (loss) per share: | ||||
| Basic | $(0.72) | — | $(1.74) | $(1.09) |
| Diluted | $(0.72) | — | $(1.74) | $(1.09) |
| Shares used to compute net income (loss) per share: | ||||
| Basic | 126.1 | 106.1 | 125.7 | 102.3 |
| Diluted | 126.1 | 106.5 | 125.7 | 102.3 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's EPS (basic)?
- Arcus Biosciences (RCUS) reported EPS (basic) of -$0.72 in Q2 2026.
- What is the long-term trend for Arcus Biosciences's EPS (basic)?
- Over 3 years (2022 to 2025), Arcus Biosciences's EPS (basic) has grown at a -3.8% compound annual growth rate (CAGR), from -$3.72 to -$3.31.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Arcus Biosciences's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude